Avalo insider plans sale after option exercise

Avalo Therapeutics, Inc. (AVTX) reports that an affiliate, Morgan Stanley Smith Barney LLC Executive Financial Services, intends to sell common stock on behalf of a party identified in the notice.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) reports that an affiliate, Morgan Stanley Smith Barney LLC Executive Financial Services, intends to sell common stock on behalf of a party identified in the notice. The planned transaction covers 679 shares of common stock in connection with an exercise of stock options for cash on 08/10/2026.

The notice also lists prior common stock sales for Mittie Doyle under a Rule 10b5-1 trading plan over the past three months, including transactions on 05/15/2026, 05/28/2026, 06/23/2026, 06/30/2026, and 07/27/2026 with share counts ranging from 679 to 4,654 shares.

Key Figures

Planned shares to be sold: 679 shares Planned transaction value: $12,439.28 Past sale 06/30/2026: 4,654 shares for $93,080.00 +2 more

5 metrics

Planned shares to be sold 679 shares Common stock tied to stock option exercise for cash on 08/10/2026

Planned transaction value $12,439.28 Aggregate value associated with 679 AVTX common shares

Past sale 06/30/2026 4,654 shares for $93,080.00 Rule 10b5-1 AVTX common stock sale for Mittie Doyle

Past sale 05/15/2026 3,000 shares for $56,280.00 Rule 10b5-1 AVTX common stock sale for Mittie Doyle

Past sale 07/27/2026 1,000 shares for $20,000.00 Rule 10b5-1 AVTX common stock sale for Mittie Doyle

Key Terms

Rule 10b5-1, Exercise of Stock Options, Form 144, Executive Financial Services

4 terms

Rule 10b5-1 regulatory

"10b5-1 Sales for MITTIE DOYLE 1500 Liberty Ridge Drive, Suite 321"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Exercise of Stock Options financial

"Common | 08/10/2026 | Exercise of Stock Options | Issuer"

Form 144 regulatory

"144: Securities To Be Sold Common | 08/10/2026"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is being reported for AVTX in this Form 144 notice?

The notice reports an intent to sell 679 shares of Avalo Therapeutics (AVTX) common stock. The shares are tied to an exercise of stock options for cash on 08/10/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.

What is the aggregate value of the planned 679-share AVTX stock sale?

The planned sale of 679 AVTX common shares is listed with an aggregate value of $12,439.28. This figure reflects the total value associated with the shares covered by the notice for the intended transaction dated 08/10/2026.

How is the AVTX stock being acquired before the planned sale on 08/10/2026?

The AVTX common stock is being acquired through an exercise of stock options on 08/10/2026. The notice states that the acquisition method is an option exercise paid in cash, after which the 679 shares are intended to be sold.

What past Rule 10b5-1 sales for AVTX stock by Mittie Doyle are disclosed?

The notice lists Rule 10b5-1 sales of AVTX common stock for Mittie Doyle on 05/15/2026, 05/28/2026, 06/23/2026, 06/30/2026, and 07/27/2026, with individual transactions ranging from 679 to 4,654 shares.

What were the largest recent AVTX stock sales under the 10b5-1 plan?

The largest reported recent sale under the Rule 10b5-1 plan is 4,654 AVTX shares on 06/30/2026 for $93,080.00. Another notable sale is 3,000 shares on 05/15/2026 for $56,280.00.

Who is identified in connection with the recent AVTX 10b5-1 stock sales?

The recent AVTX stock sales under a Rule 10b5-1 plan are identified as being for Mittie Doyle. Multiple transactions in AVTX common stock are listed for this individual between 05/15/2026 and 07/27/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 04:48 PM Accepted by SEC EDGAR 08/10/2026 - 04:47 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001918845
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AVALO THERAPEUTICS, INC.
SEC File Number	001-37590
Address of Issuer	1500 Liberty Ridge Drive, Suite 321 Wayne PENNSYLVANIA 19087
Phone	4105228707
Name of Person for Whose Account the Securities are To Be Sold	MITTIE DOYLE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	679	12439.28	53629989	08/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/10/2026	Exercise of Stock Options	Issuer			679	08/10/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MITTIE DOYLE 1500 Liberty Ridge Drive, Suite 321 Wayne PA 19087	Common	07/27/2026	1000	20000.00
10b5-1 Sales for MITTIE DOYLE 1500 Liberty Ridge Drive, Suite 321 Wayne PA 19087	Common	06/30/2026	4654	93080.00
10b5-1 Sales for MITTIE DOYLE 1500 Liberty Ridge Drive, Suite 321 Wayne PA 19087	Common	06/23/2026	1450	26100.00
10b5-1 Sales for MITTIE DOYLE 1500 Liberty Ridge Drive, Suite 321 Wayne PA 19087	Common	05/28/2026	679	10864.00
10b5-1 Sales for MITTIE DOYLE 1500 Liberty Ridge Drive, Suite 321 Wayne PA 19087	Common	05/15/2026	3000	56280.00

144: Remarks and Signature

Remarks
Date of Notice	08/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/13/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mittie Doyle
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)